Skip to content
Politically.com Search all
Menu

2025 · 3rd Quarter (July 1 - Sep 30)

NOVARTIS

Filed by TARPLIN, DOWNS & YOUNG, LLC.

Open official filing
Source: Lobbying Disclosure APIRecently refreshed. 2026-08-03 06:26:15 UTC.

Source-reported fields

Filing overview

Type
3rd Quarter - Report
Posted
Oct 20, 2025
Income
$60,000.00
Expenses
Not reported
Client
NOVARTIS
Filing UUID
ff685551-4ee4-48a0-9924-30ee03e61c50
Termination date
Not reported

Literal source text

Lobbying issues and bill citations

BUD · Budget/Appropriations

Federal budget issues

HCR · Health Issues

MINI Act, IRA, affordability, pharmaceutical innovation, transparency, intellectual property, PBMs, pharmaceutical pricing issues, drug shortages, genetically targeted therapies, EPIC Act, supply chain, drug pricing and drug discount programs in federal programs, international drug reference pricing

MMM · Medicare/Medicaid

bio pharmaceutical reimbursement issues, IRA

TRD · Trade (domestic/foreign)

tariffs

Relationship and amount limits

Bill links use only the filing year’s mathematically derived Congress plus the literal measure type and number in the issue description. Unmatched citations remain plain text. Politically.com does not join on names, infer advocacy positions, combine amendments, or calculate totals across filings.